Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients

David J. LaPorte, Adrianne C. Lahti, Bettylou Koffel, Carol A. Tamminga

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Glutamatergic dysfunction may play an important role in both the pathophysiology of schizophrenia, and impaired memory commonly observed in that disorder. NMDA receptor antagonists impair learning/memory in animal models, putatively based on its ability to block long-term potentiation (LTP) in the hippocampus. Although well studied in animal models, research in humans is limited and confounded by administration of NMDA antagonists before the learning experience. Based on presumed glutamatergic dysfunction, it was predicted that the NMDA antagonist ketamine would not effect memory in schizophrenic subjects. Bolus injections of ketamine (0.5 mg/kg) or placebo were given to seven patients with schizophrenia in this double-blind cross-over study. Immediately prior to injection, subjects were administered verbal and figural memory tests. Delayed recalls were obtained 30-45 min postinjection. In order to rule out drug-induced generalized cognitive impairments, other cognitive tasks were administered pre- and postinjection. The results indicate no differences between the drug and placebo conditions for either memory task, and no changes on the other cognitive tasks observed.

Original languageEnglish (US)
Pages (from-to)321-330
Number of pages10
JournalJournal of Psychiatric Research
Volume30
Issue number5
DOIs
StatePublished - Sep 1996

Fingerprint

Ketamine
Cognition
N-Methylaspartate
Schizophrenia
Animal Models
Placebos
Learning
Injections
Aptitude
Long-Term Potentiation
N-Methyl-D-Aspartate Receptors
Pharmaceutical Preparations
Cross-Over Studies
Hippocampus

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients. / LaPorte, David J.; Lahti, Adrianne C.; Koffel, Bettylou; Tamminga, Carol A.

In: Journal of Psychiatric Research, Vol. 30, No. 5, 09.1996, p. 321-330.

Research output: Contribution to journalArticle

LaPorte, David J. ; Lahti, Adrianne C. ; Koffel, Bettylou ; Tamminga, Carol A. / Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients. In: Journal of Psychiatric Research. 1996 ; Vol. 30, No. 5. pp. 321-330.
@article{f7b5fd77ba59482186954de63806fcf0,
title = "Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients",
abstract = "Glutamatergic dysfunction may play an important role in both the pathophysiology of schizophrenia, and impaired memory commonly observed in that disorder. NMDA receptor antagonists impair learning/memory in animal models, putatively based on its ability to block long-term potentiation (LTP) in the hippocampus. Although well studied in animal models, research in humans is limited and confounded by administration of NMDA antagonists before the learning experience. Based on presumed glutamatergic dysfunction, it was predicted that the NMDA antagonist ketamine would not effect memory in schizophrenic subjects. Bolus injections of ketamine (0.5 mg/kg) or placebo were given to seven patients with schizophrenia in this double-blind cross-over study. Immediately prior to injection, subjects were administered verbal and figural memory tests. Delayed recalls were obtained 30-45 min postinjection. In order to rule out drug-induced generalized cognitive impairments, other cognitive tasks were administered pre- and postinjection. The results indicate no differences between the drug and placebo conditions for either memory task, and no changes on the other cognitive tasks observed.",
author = "LaPorte, {David J.} and Lahti, {Adrianne C.} and Bettylou Koffel and Tamminga, {Carol A.}",
year = "1996",
month = "9",
doi = "10.1016/0022-3956(96)00018-0",
language = "English (US)",
volume = "30",
pages = "321--330",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients

AU - LaPorte, David J.

AU - Lahti, Adrianne C.

AU - Koffel, Bettylou

AU - Tamminga, Carol A.

PY - 1996/9

Y1 - 1996/9

N2 - Glutamatergic dysfunction may play an important role in both the pathophysiology of schizophrenia, and impaired memory commonly observed in that disorder. NMDA receptor antagonists impair learning/memory in animal models, putatively based on its ability to block long-term potentiation (LTP) in the hippocampus. Although well studied in animal models, research in humans is limited and confounded by administration of NMDA antagonists before the learning experience. Based on presumed glutamatergic dysfunction, it was predicted that the NMDA antagonist ketamine would not effect memory in schizophrenic subjects. Bolus injections of ketamine (0.5 mg/kg) or placebo were given to seven patients with schizophrenia in this double-blind cross-over study. Immediately prior to injection, subjects were administered verbal and figural memory tests. Delayed recalls were obtained 30-45 min postinjection. In order to rule out drug-induced generalized cognitive impairments, other cognitive tasks were administered pre- and postinjection. The results indicate no differences between the drug and placebo conditions for either memory task, and no changes on the other cognitive tasks observed.

AB - Glutamatergic dysfunction may play an important role in both the pathophysiology of schizophrenia, and impaired memory commonly observed in that disorder. NMDA receptor antagonists impair learning/memory in animal models, putatively based on its ability to block long-term potentiation (LTP) in the hippocampus. Although well studied in animal models, research in humans is limited and confounded by administration of NMDA antagonists before the learning experience. Based on presumed glutamatergic dysfunction, it was predicted that the NMDA antagonist ketamine would not effect memory in schizophrenic subjects. Bolus injections of ketamine (0.5 mg/kg) or placebo were given to seven patients with schizophrenia in this double-blind cross-over study. Immediately prior to injection, subjects were administered verbal and figural memory tests. Delayed recalls were obtained 30-45 min postinjection. In order to rule out drug-induced generalized cognitive impairments, other cognitive tasks were administered pre- and postinjection. The results indicate no differences between the drug and placebo conditions for either memory task, and no changes on the other cognitive tasks observed.

UR - http://www.scopus.com/inward/record.url?scp=0030248928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030248928&partnerID=8YFLogxK

U2 - 10.1016/0022-3956(96)00018-0

DO - 10.1016/0022-3956(96)00018-0

M3 - Article

C2 - 8923336

AN - SCOPUS:0030248928

VL - 30

SP - 321

EP - 330

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 5

ER -